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Introduction
For centuries, plants have been used as sources of medicine by 
mankind. In many developing countries, plant medicines still serve 
as the primary means of healthcare for treating various illnesses, and 
current estimates indicate the share of plant-derived drugs in these 
regions to be about 80% [1]. It is needless to say that Europe and other 
western countries have recently seen the green medicine resurgence: 
the ever increasing list of herbal products on the shelves of local 
pharmacies and health food shops is testimony to people opting to 
use natural medicines. But how about the secrets within our European 
garden plants that we might have taken for granted? Some of them have 
a long history of medicinal uses substantiated by scientiic evidence. 
It is not intended here to list herbal products that are on large scale 
production for their medicinal uses, but to give two selected examples 
from common European garden plants that highlight hidden treasures 
in our gardens. 
Traditionally, the search of novel drugs from natural sources take 
one of the two routs: the ethnobotanical and random screening approach 
[2]. he ethnobotanical approach starts by documenting the traditional 
medicinal uses of plants and screen them for biological activities that 
closely match the indicated disease condition. here are numerous 
good examples one can use to validate this approach, including the 
discovery of anticancer drugs, podophyllotoxin derivatives, from 
studies on Podophyllum species. Aremisinin from Artemisia annua 
is another perfect example of the ethnobonatical approach of drug 
discovery studies. Getting the correct or all information from the 
ethnobotanical source and even understanding the information, as well 
as the time scale required for such studies however could be seen as 
the major challenge of this approach. For those institutions that could 
aford running hungry assays (e.g. big pharmaceutical industries), 
the random screening approach using a selected unique target area 
is an alternative drug discovery approach. his approach, from a well 
deserved example of the anticancer drug taxol identiied from the 
bark of the Paciic yew tree, Taxus brevifolia, has its own success story. 
When one works in an academic institution like ours where funding is 
a major constraint, however, a combination of the ethnobotanical and 
random screening approach study seems very feasible. Hence, we select 
plants based on ethnobotancal information and use selected high-value 
targets for pharmacological screening. Whatever strategy is adopted, 
plants continued to be the source of novel, oten structurally complex, 
chemical entities. Various authors further outlined that about 70% of 
novel chemicals identiied during the last two decades are of natural 
products origin, of which over half are from plants [1]. 
Abstract
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Naturally, a drug discovery scientist looks a lora that has not yet 
been studied and probably those in the tropics and other exotic places 
with a rich history of traditional uses. here are lots of incentives in 
studying such plants as the continued deforestation, desertiication and 
over exploitation of endemic plants could lead to their extinction prior 
to their secret treasures (chemical constituents) being documented. 
Hence, our research laboratories for over two decades have studied 
several endemic plants from North and South America, Africa, Asia 
and Australia. hrough systematic pharmacological screening followed 
by bioassay-guided isolation studies, we have identiied various 
bioactive compounds belonging to several chemical classes [3]. hese 
studies also revealed numerous novel and known chemical entities that 
could be used for standardization, and/or modernization of traditional 
herbal medicines. During the course of our study, particularly during 
the 1990’s, we also noticed that there actually exist a big gap in 
European medicinal plants, with due respect to their chemistry and 
pharmacology versus their claimed medicinal uses. Surprisingly, the 
chemistry and pharmacology of many European plants, including 
many acknowledged herbal medicines have not been fully documented. 
he reasons for these are:
1. here is a general perception that European medicinal 
plants are exhaustively studied, and there is little chance of getting a 
pharmacological hit. Most of the earlier studies on European medicinal 
plants, however, have limitations as the high value targets indentiied in 
recent years were not accounted for. Similarly, our capability today in 
the isolation and identiication of chemical compounds from natural 
sources is much better than some 50 years ago. Hence, compounds that 
were diicult to isolate/identify and exist in trace amounts can still be 
explored from common European plants.
2. It is quite diicult to get funding to document the 
chemistry and pharmacology of common European plants. European 
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pharmacognosists are, therefore, more involved in studying medicinal 
plants of exotic places than local plants.
In this brief perspective, the chemistry and pharmacology of two 
selected exemplary European common garden plants (Figure 1) studied 
in our laboratories during the last two years are presented.
Case Example 1–Berberis darwinii
First, let us see an example of botanical treasures discovered by one 
of the most outstanding British scientists of the 19th century. One might 
wonder who–perhaps the British chemist Michael Faraday among 
many other famous scientists of that era; but he was not really known for 
studying medicinal plants. How about Charles Darwin, whose theory of 
evolution has drastically shaped science and the human society, as we 
know it today? Darwin’s legendary ive-year voyage on H.M.S. Beagle 
is known to be the foundation for his famous book “On the Origin 
of Species” or the theory of evolution [4]. Besides his widely reported 
scientiic observation in the Galapagos Islands, Darwin meticulously 
collected exotic plants and animals he encountered during his South 
American trip. One of the plants that he discovered in 1835, and later 
named in his honour, was Darwin’s Barberry (Berberis darwinii). 
his native plant to southern Chile and Argentina is known to be 
introduced to Britain in 1849 by William Lobb [5]. Darwin’s Barberry 
is now a popular garden and hedging shrub cultivating all over the 
world. he Royal Horticultural Society has also recently given it an 
Award of Garden Merit [6]. If one wonders why, this is a fast growing 
an evergreen plant with dark green shiny leaves and impressive orange 
lowers in spring that lead to purple-black berries in summer (Figure 
1). he mature berries are known to have been eaten by native people in 
South America for centuries. Apparently, they are acidic and sour, but 
birds in the Britain greedily feast on them. 
If one has to cut the wood of Darwin’s Barberry and remove the 
bark, the woody tissues and bark appear bright yellow in colour (Figure 
2); this is due to a chemical called berberine. It is worth noting that 
plants containing berberine, such as Goldenseal (Hydrastis canadensis), 
and Chinese Goldthread (Coptis chinensis), are highly valued for their 
medicinal uses. But berberine in these plants is found together with 
other structurally related alkaloids, such as hydrastine, palmatine, 
and/or jatrorrhizine [7]. We have recently conducted studies on the 
chemistry and pharmacology of Darwin’s Barberry [7]. As shown in 
Figure 3, HPLC chromatograms revealed the stem bark contained 
just one UV-visible component, berberine, not just from the alkaloid 
fraction, but the crude methanolic extract. his inding was remarkable 
given that plants normally contain a mixture of thousands of diferent 
chemicals in their tissues. One of the potential medicinal values of this 
plant and its chemical berberine that many laboratories looked at so far 
is for combating Alzheimer’s disease (AD). 
AD is principally associated with progressive neurodegenerative 
pathological changes in the forebrain cholinergic system, though other 
brain areas are also known to be afected. It has been well established that 
the loss of cholinergic system, and/or decreased levels of acetylcholine 
is associated with pathological accumulation of β-amyloid protein 
in the afected areas. One popular therapeutic strategy for AD is, 
therefore, through enhancing the cholinergic system via inhibition of 
the enzyme (acetylcholinesterase) that breaks down acetylcholine [8]. 
Agents that reduce the accumulation of β-amyloid or those preventing 
-amyloid mediated, and/or oxidative-stress associated neurotoxicity 
could also have beneicial efect in managing AD. Remarkably, Darwin’s 
Barberry extract and its chemical (berberine) have potential to treat 
AD through the entire above mentioned multiple targets [7]. here is 
currently a lurry of scientiic activities worldwide to synthesize drugs 
related to this natural product. It is hoped that a more active and easily 
obtainable anti-AD drug could be found based on this model of natural 
product. Given that B. darwinnii ofers a high yield and relatively pure 
Figure 1: Photographs of Berberis darwinnii (A) and Bergenia cordifolia (B) 
taken from the author’s garden.
Figure 2: Stem wood (A) and steam bark (B) of B. darwinnii appearing yellow 
due to their principal constituent, Berberine.
A B
C
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Figure 3: HPLC chromatograms of pure Berberine (A), stem bark (B), stem 
wood (C) and leaves (D) extract of B. darwinnii. The extracts were obtained by 
macerating the plant materials in methanol. HPLC analysis was carried out as 
described previously [7]. Berberine has a retention time of 6.9 min.
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source of berberine, its potential as anti-AD therapy deserves further 
investigation. 
Berberine has also shown to display numerous other 
pharmacological properties, including antimicrobial efects against 
pathogenic bacteria such as Vibrio cholera, Shigella dysenteriae, 
Salmonella species and various multidrug resistant bacterial strains [9-
14]. Berberine is widely regarded as a potent anti-inlammatory agent 
[15-19] that could be explained in part by its action at the molecular 
level as an inhibitor of leucocytes adhesion to activated endothelial 
cells [20], cyclooxygenase-2 expression [21,22], NF-κB activation [23], 
cytokines expression [24], etc. In conjunction with its anti-inlammatory 
and antioxidant efects, berberine has been shown to display anti-
atherosclerosis property [25,26]. he lipid lowering efect of barberine 
has been reviewed by various authors [27-29], and such efect could 
partly explain its reputed cardio- and hepatoprotective efects [30,31]. 
In this connection, the potential of barberine in combating fatty liver 
diseases has been emphasised in recent years [32-34]. Once again, the 
protective role of berberine in mammalian tissues could be linked to 
its antioxidant and anti-inlammatory efects as the expressions of 
multipotent biomolecules, such as COX-2, proinlammatory cytokines, 
such as TNF-α and inducible nitric oxide synthase are all inhibited by 
berberine [35].
he other productive area of research on berberine and berberine-
containing plants have been on their potential therapeutic potential for 
diabetes [36-38], and associated diseases such as diabetic neropathy 
[39] and nephropathy [40,41]. Among the various possible mechanism 
of berberine’s antidiabetic action are through inhibition of peroxisome 
proliferator-activated receptors expression [42,43] carbohydrate 
digestion [44], various signalling pathways [45], modulation of protein 
tyrosine phosphatase 1B activity [46], activation of glucose transport 
pathway of GLUT-1 [47], promoting the secretion of glucagon-like 
peptide secretion [48], increasing insulin receptor expression [49], 
control of lipid dysregulation [50] antioxidant mechanisms and aldose 
reductase inhibitory activity [51], and anti-inlammatory mechanisms 
[52].
Berberine and berberine-containing plants are also highly sought 
ater for their potential anticancer efects. Numerous studies have 
highlighted that berberine not only directly induces apoptosis in cancer 
cells [53-55], but also sensitise them to other chemotherapeutic agents 
and radiation therapy [56,57]. Suppression of gene transcription [58], 
reactive oxygen species mechanisms [59], mitochondrial and caspase 
pathways [60], anti-calmodulin property [61] inhibition of key kinase 
enzymes [62], and many other multiple mechanisms [63] have been 
suggested as the possible mode of action for berberine-induced 
apoptosis in cancer cells. Inhibition of cancer metastasis through 
downregulation of activities and expression levels of key enzymes, such 
as heparanse [64] and matrix metalloproteinases 2 and 9 [65], are also 
among the various anticancer study reports on berberine. 
In view of the numerous above mentioned exemplary 
pharmacological activities of berberine, the inding the common 
garden plant, B. darwinni, as a good source of this therapeutically useful 
drug, is very signiicant.
Case Example 2–Bergenia cordifolia
To date, around 300 million people worldwide are known to sufer 
from diabetes. Hand in hand with diabetes, obesity has become the most 
serious public health problem worldwide, and its prevalence during the 
last few decades has dramatically increased with epidemic proportions 
[66]. α-Glucosidase and pancreatic lipase enzymes inhibition are two 
established strategies for targeting diabetes and obesity respectively [67-
69]. Other strategies that showed beneit in treating diabetes-related 
diseases are antioxidant therapeutics [70]. In our laboratories, several 
hundreds of plants identiied from their traditional medicinal uses, 
and/or scientiic reports are screened for digestive enzyme inhibitions 
and antioxidant efects. Plant extracts that ofer multifunctional efects 
are given priority, and their active constituents subjected to isolation 
and structural elucidation. One of the promising plants identiied in 
our laboratories was the most widely grown garden plant in Europe, B. 
cordifolia. hough the plant is known to predominantly contain arbutin 
and bergenin, no comprehensive phytochemical or pharmacological 
analysis has ever been reported on it.
In addition to potent antioxidant efect, we found that the rhizome 
extract of B. cordifolia was about 103-fold more active in inhibiting 
α-glucosidase than the standard antidiabetic drug, acarbose [71]. 
We further demonstrated that this enzyme inhibition by the extract 
was not a non-selective pharmacological efect as 111-times more 
potency in α-glucosidase inhibition was observed when compared to 
mitigation of acetylcholinesterase enzyme activity. By excluding the 
major constituents (arbutin and bergenin) that do not account both 
for the antioxidant and potential antidiabetic properties, the search for 
the minor constituents with the indicated biological activities lead to 
the identiication of three compounds: catechin 3-O-gallate, catechin 
3,5-di-O-gallate and 1,2,4,6-tetra-O-galloyl-β-D-glucopyranoside 
[71]. he latter two compounds were rare natural products isolated as 
potent natural antilipase [72] and antiviral agents [73], respectively. 
In addition to displaying the highest level of antioxidant efects, these 
two compounds further scored 78 and 159-fold respectively more 
potent α-glucosidase enzyme inhibition than acarbose [71]. Hence, 
the identiied compounds and the plant have enormous therapeutic 
potential for treating diabetes, obesity and associated diseases. 
It is also worth noting the pharmacological activities of the two most 
abundant B. cordifolia constituents; bergenin and arbutin. he most 
notable biological activity of arbutin is potent inhibition of tyrosinase 
enzyme that attribuites to its use as a commercial skin lightning agent 
[74-76]. On the other hand, bergenin has numerous biological efects, 
including antiviral [77], antiulcer [78], antiarethmetic [79], antidiabetic 
and anti-obesity [80], anti-inlammatory [81], immunomodulatory 
[82] and hepatoprotective [83-85] efects.
We have numerous other examples where European garden plants 
have been shown to display unique pharmacology and chemistry. hese 
plants, as with other plants in exotic places, need to be looked at not 
only for validating their centuries-old medicinal uses, but also as a 
source of valuable medicines.
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